On the other hand, ERRC1, FANCA,MSH2, XPA, and SNM1A have been well documented asmarkers of resistance to chemotherapy in solid tumors (7,12-, , 15) Currently, PARP1 is atherapeutic target in the treatment for patients with BRCA1- orBRCA2-mutated BC (16). This evidence concerns the gene BRCA1 and breast cancer.